CND Life Sciences, a pioneering diagnostics company developing innovative tools for the detection of neurodegenerative diseases, raised $13.5M in Series A3 equity financing led by VILAS Ventures.

The funding will accelerate CND's commercial growth and R&D initiatives, expanding access to its flagship product, the Syn-One Test-the first commercially available skin-based diagnostic that visualizes and quantifies abnormal alpha-synuclein, a key marker of synucleinopathies such as Parkinson's disease.